IDH1-VAC (IDH1 R132H Peptide Vaccine)
IDH1-vac
not stated in source · Single arm
newly diagnosed IDH1 R132H astrocytoma
vaccine-induced immune response: 93.3%, 28 of 30 evaluable
NOA-16 · NCT02454634
Disease Pipeline Tools IDH-mutant glioma
IDH-mutant glioma
Programs, trials, and reported response and survival for IDH-mutant glioma.
IDH-mutant glioma
Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.
3 arms have a reported figure in this set.
IDH1-vac
not stated in source · Single arm
newly diagnosed IDH1 R132H astrocytoma
vaccine-induced immune response: 93.3%, 28 of 30 evaluable
NOA-16 · NCT02454634
Olutasidenib 150 mg BID
150 mg · Single arm
relapsed or refractory IDH1-mutant glioma (26 enrolled, 25 evaluable)
disease control rate: 48%, 12 of 25
Olutasidenib Phase 1/2 (glioma cohort) · NCT03684811
Vorasidenib 40 mg daily
40 mg · ITT
grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery only (n = 168 vs 163)
Comparator: placebo
median time to next intervention, placebo: 17.8 months, primary analysis
INDIGO · NCT04164901
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.